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Abstract Therapeutic targeting of melanoma antigens
frequently focuses on the melanocyte differentiation or
cancer-testis families. Antigen-loss variants can often
result, as these antigens are not critical for tumor cell
survival. Exploration of functionally relevant targets has
been limited. The melanoma inhibitor of apoptosis protein
(ML-IAP; livin) is overexpressed in melanoma, contribut-
ing to disease progression and treatment resistance.
Improved understanding of the signiﬁcance of ML-IAP
immune responses in patients has possible therapeutic
applications. We found ML-IAP frequently expressed in
melanoma metastases by immunohistochemistry. To assess
spontaneous immunity to ML-IAP, an overlapping peptide
library representing full-length protein was utilized to
screen cellular responses in stage I–IV patients and healthy
controls by ELISPOT. A broad array of CD4
? and CD8
?
cellular responses against ML-IAP was observed with
novel class I and class II epitopes identiﬁed. Speciﬁc HLA-
A*0201 epitopes were analyzed further for frequency of
reactivity. The generation of speciﬁc CD4
? and cytotoxic
T cells revealed potent functional capability including
cytokine responsiveness to melanoma cell lines and tumor
cell killing. In addition, recombinant ML-IAP protein used
in an ELISA demonstrated high titer antibody responses in
a subset of patients. Several melanoma patients who
received CTLA-4 blockade with ipilimumab developed
augmented humoral immune responses to ML-IAP as a
function of treatment which was associated with beneﬁcial
clinical outcomes. High frequency immune responses in
melanoma patients, associations with favorable treatment
outcomes, and its essential role in melanoma pathogenesis
support the development of ML-IAP as a disease marker
and therapeutic target.
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Introduction
Many melanoma antigens have been identiﬁed that are the
targets of both cellular and humoral immune responses. The
melanocyte differentiation antigens expressed in both mel-
anomas and normal melanocytes have been extensively
studied as both the targets of spontaneous immune respon-
ses as well as utilized in strategies to augment immunity
with therapeutic intent [1]. In addition, the cancer-testis
antigens, such as MAGE [2, 3] and NY-ESO-1 [4, 5], have
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present attractive therapeutic targets as their expression is
limited to a subset of melanomas and they are not expressed
in normal tissues other than the germ cells of testes, pla-
centa, and fetal ovary. Strategies to therapeutically target
these classes of antigens frequently lead to antigen-loss
variants [6–12] and progression of disease. An important
goal in cancer therapeutics, therefore, is the identiﬁcation of
antigens that will less likely result in antigen-loss variants
due to their essential role in melanoma pathogenesis. Some
deﬁned melanoma antigens such as b-catenin [13] have
been linked to function. Further exploration of functionally
relevant antigen targets for melanoma has potential clinical
applications.
The inhibitor of apoptosis (IAP) family of proteins
represents key regulators of apoptosis that function through
the prevention of caspase activation [14] and the regulation
of TNF signaling. The IAPs are frequently over expressed
in a number of cancers, and their expression is increased by
tumor cells in response to chemotherapy or radiation [15].
Speciﬁcally, the melanoma inhibitor of apoptosis protein
(ML-IAP; livin) is strongly expressed in a variety of human
cancers including melanoma [16–18], but has limited
expression in normal adult tissues [19–21]. The high
expression of ML-IAP in tumors has been associated with a
poor prognosis. Expression of ML-IAP has been shown to
provide apoptosis resistance in non-small cell lung cancer
cells [21] and melanoma.
ML-IAP binds caspases 3, 7, and 9, and may function as
a SMAC sink, resulting in the blockade of the death
receptor and mitochondria based apoptotic pathways
[22, 23]. The BIR domain of ML-IAP contains an evolu-
tionary conserved sequence that is required for its anti-
apoptotic activity. In this way, ML-IAP offers melanoma
cells a distinct survival advantage during tumor progres-
sion as well as a mechanism for resistance to chemo-
therapy, radiation, and hypoxic conditions [24]. The
downregulation of ML-IAP in various preclinical models
leads to increased apoptosis, reduced tumor cell growth,
and sensitization to chemotherapy [25].
ML-IAP has previously been identiﬁed as a target of
immune-mediated tumor destruction in patients receiving
vaccination with autologous, irradiated melanoma cells
engineered to secrete granulocyte–macrophage colony
stimulating factor (GM-CSF) [26]. In addition, spontane-
ous cytotoxic T lymphocyte (CTL) responses to ML-IAP
epitopes have been found in melanoma patients and a
limited number of healthy controls [27]. In the current
study, we utilized a library of overlapping peptides to
screen for T cell responses by ELISPOT in stage I–IV
melanoma patients as well as normal donors, thus not
limiting our assessment to a particular haplotype. Humoral
immune responses were assessed utilizing recombinant
ML-IAP protein in an ELISA. Spontaneous immune
responses to ML-IAP in melanoma patients demonstrate
both speciﬁc cellular and humoral activity as well as cor-
relations with favorable clinical outcomes.
Materials and methods
Tissues and sera
Tumor and peripheral blood samples were obtained from
patients on Dana-Farber/Harvard Cancer Center Institu-
tional Review Board approved protocols. Tumor cell lines
were established from harvested fresh tissues that under-
went mechanical and enzymatic digestion and in vitro
expansion. Cell cultures were maintained in Dulbecco’s
modiﬁed Eagle medium containing 10% (vol/vol) fetal calf
serum (FCS) and penicillin/streptomycin. Peripheral blood
was collected in heparinized tubes from normal donors and
patients diagnosed with stages I–IV melanoma. Peripheral
blood mononuclear cells (PBMC) were isolated by gradient
centrifugation using Ficoll-Paque Plus (GE Healthcare
Bio-Sciences, Piscataway, NJ).
Immunohistochemical analysis and scoring
All specimens were standard, formalin-ﬁxed, parafﬁn-
embedded tissue blocks for morphological analysis.
Hemotoxylin-eosin stained sections of each lesion were
reviewed to verify the diagnosis and assess the presence of
representative lesional material. For patients who had
peripheral blood obtained for immune analyses, blocks of
metastatic visceral deposits were available for immuno-
histochemical analysis in eight cases. This was performed
utilizing a ML-IAP speciﬁc antibody as previously descri-
bed [26]. Mouse IgG1 (BD biosciences, cat#: 557273) was
used as a control. The extent of ML-IAP expression in
tumor cells was estimated microscopically by two pathol-
ogists who were blinded to the patient’s data and graded
as follows: negative (0%); ? (\20%); ?? (20–60%); and
??? ([60%).
ELISPOT assay
For T cell stimulation, 1 9 10
6 PBMC were initially cul-
tured with 1 lg/ml of each peptide in overlapping peptide
pools or 10 lg/ml single peptide in the presence of 10 U/ml
IL-2 (BD Biosciences) for 1 week. For ELISPOT analyses,
5 9 10
4 cells/well were placed on a 96-well plate (Milli-
pore, Bedford, MA) pre-coated with anti-c-IFN Ab
(Mabtech, Cincinnati, OH). These cells were restimulated
with the same peptides at 10 lg/ml and autologous PBMC
overnight. The plates were washed and probed with
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tech). c-IFN spots were developed with NBT and BCIP
(Promega, Madison, WI), and counted using an Immuno-
spot reader (C.T.L. Cellular Technololgy Ltd, Shaker
Heights, Ohio). Samples were performed in duplicate. The
HIV peptide L11 (LLFGYPVYV) was utilized as a control.
For determination of CD4
? and CD8
? T cell responses to
individual peptides ([90% purity), peptide-pretreated
PBMC were incubated with either CD4 or CD8 microbeads
(MiltenyiBiotech, Auburn, CA). Cells were depleted of
either CD4
? or CD8
? T cells through MACS separation
columns (MiltenyiBiotech) and were then stimulated with
the same peptides for ELISPOT analysis. To analyze HLA-
A*0201 reactivity in melanoma patients and normal
donors, ML-IAP peptides I280, JS90, and I237 were used.
HLA-A*0201 peptides for ﬂu(GILGFVFTL) and MART-
1(EAAGIGILTV) were utilized for comparisons.
Generation of antigen-speciﬁc CTL
To determine the HLA status from donor blood, PBMC
were ﬁrst stained with ﬂuorescence conjugated anti-HLA-
A2 Ab (BB7.2) (AbD serotec, Oxford, UK), and analyzed
by ﬂow cytometry. Genotyping for HLA-A2 and DR
alleles were performed by the American Red Cross by PCR
ampliﬁcation with sequence-speciﬁc primers and sequence-
based typing. For HLA-A*0201 peptide reactivity, T2 cells
were grown in RPMI 1640 supplemented with 10% FCS
and utilized in ELISPOT.
Generation of autologous activated B cells for peptide
presentation was performed as previously described [28].
Brieﬂy, NIH 3T3-CD40L cells are stably transfected with
CD40 ligand expression vector to express CD40 ligand and
were maintained in F12/DMEM supplemented with 10%
FCS and 400 lg/ml G418. PBMC were cocultured with
irradiated (96 Gy) NIH 3T3-CD40L cells in the presence
of 10 ng/ml IL-4 (R&D Systems, Minneapolis, MN) and
0.55 lM cyclosporine A (Sigma, St. Louis, MO) for
3–5 days. Activated B cells were maintained by coculture
with NIH 3T3 CD40L cells in Iscove’s Modiﬁed Dul-
becco’s Medium (IMDM) supplemented with 10% FCS and
10 ng/ml IL-4. CD8
? T cells were isolated by positive
selection using microbeads (MiltenyiBiotech). Epitope-
speciﬁc T cells were stimulated in the presence of 10 U/ml
IL-2 with autologous activated B cells that have been pulsed
with relevant peptide (New England Peptide, Gardner, MA)
and irradiated (32 Gy). Manufactured T cells were cultured
in RPMI 1,640 supplemented with 10% human AB sera
(Mediatech, Herndon, VA) and 100 U/ml IL-2. After two to
four rounds of stimulation, phenotypic and functional
analyses of the CD8
? T cells were performed. For genera-
tion of peptide-speciﬁc CD4 T cells, patient PBMCs were
treated with 10 lg/ml peptide in the presence of 10 U/ml of
IL2 for 1 week. Isolated CD4
? T cells were restimulated
withirradiatedautologousPBMCsinthepresenceof10 lg/ml.
The CD4
? or CD8
? T cell cultures were further enri-
ched by IFN-c selection (MiltenyiBiotech), expanded and
maintained with irradiated PBMC (32 Gy), 1% PHA
(Invitrogen, Carlsbad, CA), and 100 U/ml IL-2.
Proliferation assay
1 9 10
4 cells/well T cells were cocultured with 2 9 10
4
irradiated melanoma lines for 2 days, and further pulsed
with [
3H]thymidine (0.5 lCi H
3/well) overnight. The
incorporated radioactivity was measured in a liquid scin-
tillation counter.
Cytotoxic activity assay
Functional activities of antigen-speciﬁc cytotoxic T lym-
phocytes (CTL) were further analyzed with a DELFIA

cell cytotoxicity kit (PerkinElmer, Waltham, MA)
according to manufacturer’s instructions. Brieﬂy, 1 9 10
6
T2 cells or melanoma cell lines as target cells were labeled
with 5 ll DATDA for 30 min at 37C. After washing,
5 9 10
3/well labeled cells were mixed with antigen-
speciﬁc CTLs at the indicated ratio. Supernatants were
counted in a Vector
TM
ﬂuorescence plate reader (Perkin-
Elmer). All assays were performed in duplicate. Percent
cytotoxicity was deﬁned as (sample-spontaneous release)/
(total release-spontaneous release) 9 100.
ELISA
Full-length MLIAP was cloned in frame into the pET-41b
vector (Novagen, Gibbstown, NJ) and integrity of the
construct veriﬁed by sequencing (molecular biology core
facilities, Dana-Farber Cancer Institute). His-tagged
ML-IAP protein was expressed in E. coli rosetta 2 (DE3)
(Novagen, Gibbstown, NJ) with 0.1 mM IPTG for 2 h at
30C and puriﬁed by afﬁnity chromatography using
HisTrap
TM
FF nickel columns (GE Healthcare Bio-Sciences,
Piscataway, NJ), and further desalted using desalt columns
(GE Healthcare Bio-Sciences). Purity of recombinant
ML-IAP protein was conﬁrmed by acrylamide electropho-
resis, Coomassie blue staining, and Western blot as previ-
ously described [26]. Seventy-seven pmol recombinant
his-tagged ML-IAP protein and LEHHHHHHHH peptide
as a control were adsorbed in coating buffer (15 mM
Na2CO3, 30 mM NaHCO3, pH 9.6) to Nunc-Immno-plates
overnight at 4C. Plates were then washed with PBS and
blocked with 2% nonfat milk in PBS. The plates were again
washed with PBS and 100 ll per well of sera (diluted 1:500
in 2% nonfat milk) were added and incubated overnight at
4C. Plates were then extensively washed with PBS/Tween-20,
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anti-human IgG (H?L) Ab (Zymed, Carlsbad, CA) diluted
1:2000 in 2% nonfat milk for 1 h at room temperature. The
plates were again extensively washed in PBS/Tween-20 and
developed with the addition of 70 ll substrate (DAKO,
Carpinteria, CA). The reactions were stopped with the
addition of 35 ll of 1 N HCl. Plates were read at an optical
density (O.D.) of 450 nm. All samples were performed in
duplicate. Values were reported as the mean O.D. of the
sample wells minus the mean O.D. from wells coated with
tag peptide alone.
Statistical analysis
All ELISPOT samples and their negative controls were run
in duplicate. The spots/well were counted using Immuno-
Spot software Version 3 (Cellular Technology Ltd., Shaker
Heights, Ohio, USA). To screen for cellular immune
responses in stage I–IV melanoma patients, the mean
number of spots in sets of overlapping peptides were
compared with the mean number of spots in the negative
controls using a two-sample T test. A minimum of 10 or
more spots per well was required for the peptides and at
least 3 times more spots in the peptides than in the controls.
A set of peptides was considered for further study if the
probability was less than 10% that the average number of
spots in the peptide group was equal to the average number
in the control. Individual peptides were compared with
controls using similar methodology.
Antibody titers of ML-IAP by ELISA were compared for
melanoma patients and controls. Normality of the antibody
data was assessed using Shapiro-Wilks test. Comparisons of
antibody levels in controls with melanoma, or pair-wise
comparisons of controls with stage I–II, or stage III–IV
melanoma were performed using Wilcoxon rank-sum tests
due to non-normality of the data. Statistical signiﬁcance
was deﬁned as a P value of\0.05. A Bonferroni correction
was used to adjust for multiple, pair-wise comparisons.
Results
ML-IAP expression in patient tumors
Visceral metastatic tumors from eight-stage IV patients
who had parafﬁn blocks available and consented to having
their peripheral blood analyzed for immune responses were
analyzed for ML-IAP expression by immunohistochemis-
try (Fig. 1a). Levels of ML-IAP expression in tumors were
scored (?, ??, ???). One patient tumor had 3? staining,
3 patient tumors had 2? staining, 3 patient tumors had 1?
staining, and one tumor had no detectable expression. Due
to the limited size of primary melanomas and tumor
specimens involving lymph nodes (stage III), these samples
were not available for analyses.
T cell responses to ML-IAP overlapping peptide library
To gauge the incidence of cellular immune responses to
ML-IAP in melanoma patients, a series of 15–18 mer
peptides were generated to cover the full-length protein
sequence with 10 mer overlap between each individual
peptide (Fig. 1b). A total of 45 peptides were divided into 6
peptide pools. PBMC for stage I–IV melanoma patients
were stimulated with the peptide pools for 1 week, and
then stimulated a second time with the same peptide pools
for readout of the ELISPOT assay. Multiple peptide pools
of ML-IAP-induced T cell responses (Fig. 1c, d, and sup-
plemental Figure 1A). The highest frequency of T cell
responses in stage I/II patients occurred with IAP 25–32
and IAP 40–45, whereas in stage III/IV patients the highest
frequencies of responses were found in IAP25-32 and
IAP40-45. Cellular responses were also observed in some
healthy donors (HD).
To conﬁrm speciﬁc T cell immunity, puriﬁed ([90%)
individual peptides from the ML-IAP peptide pools were
further assessed by ELISPOT. If sufﬁcient PBMCs were
available, the relevant contribution of CD4
? or CD8
? T cell
responses induced was examined by CD4/CD8 depletion
(Fig. 2a). CD4
? responses dominated individual ML-IAP
peptide reactivity. The frequency of T cell responses to
identiﬁed peptides was also examined. As shown in sup-
plemental Figure 1B, IAP15, IAP31, and IAP35 induced T
cell response in stage I patients. T cell response to IAP21,
26, 39, and 44 were observed in stage III and IV patients.
CD4
? T cells for IAP26, IAP35, and IAP44 were gen-
eratedfrompatientPBMCs.Antibodyblockingexperiments
indicated that a HLA DQ antibody inhibited IAP26-induced
CD4
? T cell responses (supplemental Figure C), whereas a
HLA DR antibody abrogated IAP35 and IAP44-induced
CD4
? T cell responses (Fig. 2b, c upper panels). Genotyp-
ing of these patients revealed that they were DQA1*05,
DRB1*03/04, and DRB1*13/15. The responses of IAP35
and IAP44-speciﬁc CD4
? T cells to melanoma lines were
furtherexamined.AsdepictedinlowerpanelsofFig. 2band
c, IAP35 and IAP44 CD4
? cells had substantial prolifera-
tion to the HLA DRB1*04 melanoma cell line K028, and
HLA DRB1*13 melanoma cell line COO2, respectively. In
contrast, melanoma lines with alternate HLA DRB1 hap-
lotypes did not result in signiﬁcant proliferation.
T cell responses of melanoma patients to HLA-A*0201
binding epitopes of ML-IAP
As a result of the overlapping peptide screening, individual
peptides IAP26 and IAP35 revealed CD8
? responses in
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? responses in patient 29 and patient 71,
respectively. Since patients 29 and 71 were class I geno-
typed to be HLA-A*0201, we examined whether HLA-
A*0201 binding epitopes existed for peptides IAP26 and
IAP35 by peptide prediction programs, HLA peptide
binding predictions (http://www-bimas.cit.nih.gov/molbio/
hla_bind/) and MHC class I binding peptide prediction
server (http://bioinformatics.uams.edu/mirror/propred1/).
The results of this analysis revealed potential HLA-A*0201
afﬁnity peptide in IAP35 peptide identiﬁed as IAP237
(CLDRAVSIV, binding score: 26). In contrast, the binding
scores of HLA-A*0201 peptides in IAP26 were very low.
Given the frequency of the HLA-A*0201 haplotype
within the melanoma population, we next examined
responses in HLA-A*0201 patient PBMC to IAP237. To
gain additional context for these responses, we also
examined the frequency of T cell responses to previously
identiﬁed HLA-A*0201 ML-IAP peptides IAP280, JS34,
and JS90 [26, 27] as well as peptides representing ﬂu
and the melanosomal differentiation antigen MART-1
(Fig. 3a). PBMC from normal HLA-A*0201 donors were
also assessed for comparisons. IAP280, IAP237, and JS90
peptides induced detectable T cell responses in stage I–IV
melanoma patients (Fig. 3b). As expected patients dem-
onstrated reactivity to ﬂu peptide. No reactivity was noted
for the JS34 peptide in our tested patient population.
Finally, we investigated additional predicted HLA-
A*0201 peptides that were represented but relatively low
CD8
? responses in our overlapping peptides screening
since longer peptides possess lower binding afﬁnities.
Individual peptide IAP21 (CQFLLRSKGRDFVHSV) con-
tained predicted HLA-A*0201 peptide IAP154 (LLRSKG
RDFV, binding score: 24.2) and IAP158 (KGRDFVHSV,
binding score: 4.328). Individual peptide IAP26 (AAPVA
PSVPASGYPEL) contained IAP192 (SVPASGYPEL,
binding score 2.8). IAP154 and IAP192 did demonstrate
Fig. 1 ML-IAP is frequently
expressed in metastatic
melanoma deposits. a Example
of patient tumor staining
positive for ML-IAP by
immunohistochemistry of
parafﬁn tissues (right) and
isotype control (left). b Peptide
sequence for isoforms a and b
of the ML-IAP protein with
corresponding overlapping
peptides generated. Highlighted
are sequences representing the
previously recognized HLA-A2
peptides JS34, JS90, and
IAP280. c Examples of T cell
responses to overlapping
peptides. Patient 29 responding
to peptide pool IAP25-32 and
patient 71 responding to peptide
pool IAP33-39. d ELISPOT T
cell responses to overlapping
peptide pools in stage I–IV
melanoma patients. PBMC were
cultured with overlapping
peptide pools of MLIAP for
1 week in the presence of
10 U/ml IL-2, and further
restimulated with either L11
peptide (negative control) or the
same peptide pools. Reported is
the number of patients with
positive responses to the
depicted peptide pool by stage
as well as for healthy donors
(HD). The total refers to the
number of patients in each stage
that underwent peptide pool
screening
Cancer Immunol Immunother (2012) 61:655–665 659
123low frequency of reactivity in stage I–IV melanoma patients
(Fig. 3b). There was no detectable reactivity for IAP158.
Generation and functional characterization
of IAP237-speciﬁc CTL
To determine the functional signiﬁcance of identiﬁed epi-
tope-speciﬁc CTL, IAP237 CTL were generated using
CD40L activated B cells as antigen presenting cells from
normal HLA-A*0201 donors (Fig. 4). T2 cells in the pres-
ence of 10 lg/ml peptide revealed functional and speciﬁc
activities including target killing (Fig. 4a). In contrast,
IAP237 CTLs exhibited different abilities to lyse HLA-
A*0201 positive melanoma cell lines that express ML-IAP
(Fig. 4b).ThekillingactivitiesagainstK029andK028were
enhanced in the presence of 10 lg/ml I237 peptide. K008
and K028 melanoma cell lines have low expression
of ML-IAP by immunoblotting, while K029 has strong
ML-IAP expression. All cell lines have evidence for
ML-IAPexpressionbyRT-PCR(datanotshown).TheK008
melanoma cell line is genotypically HLA-A*0201, but fails
toexpressHLAA2moleculesonitssurfaceasdeterminedby
ﬂow cytometry. As a result, the K008 cell line experienced
less cytotoxic killing as compared to other cell lines tested.
I280 and JS90-speciﬁc CTL also demonstrated similar pat-
terns of activity against tumor lines (data not shown).
Humoral immune responses of melanoma patients
to ML-IAP
To further characterize these immune responses to ML-
IAP, we evaluated the antibody responses to ML-IAP in
our melanoma patient population. Recombinant ML-IAP
protein was generated and purity conﬁrmed by Coomassie
Fig. 2 T cell responses of melanoma patient PBMC to ML-IAP
individual peptides. a CD4
? responses dominate cellular responses to
ML-IAP peptides. T cell responses induced by individual ML-IAP
peptides were further investigated for CD4
? and CD8
? responses.
PBMC from patients were cultured with the individual peptide for
1 week. CD4
? or CD8
? T cells were isolated from the peptide-
pretreated patient PBMC by relevant depletion, and these cells were
restimulated with either L11 or the individual peptide for ELISPOT
analysis. Responses for non-depleted, CD4 depleted, and CD8
depleted are presented. b and c Generation of IAP35 and IAP44-
speciﬁc CD4
? T cells. CD4
? T cells were multi-stimulated with
IAP35 or IAP44-pulsed autologous PBMC cells. The response of
IAP35 or IAP44-speciﬁc CD4
? T cells is inhibited by a HLA DR
blocking antibody (L243). The proliferative response of IAP35 or
IAP44-speciﬁc CD4
? T cells to melanoma lines were further assessed
by H
3 uptake assay
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123staining (Fig. 5a, left panel) and immunoblot analysis uti-
lizing a ML-IAP-speciﬁc monoclonal antibody [26]
(Fig. 5a, middle panel). Patients whose sera revealed sig-
niﬁcant titers of antibodies to ML-IAP by ELISA were
conﬁrmed for speciﬁcity by immunoblotting (Fig. 5a, right
panel). Sera from normal donors and patients with stage
I–IV melanoma were analyzed by ELISA (Fig. 5b). Several
melanomapatientshadhighertitersofantibodyresponsesto
ML-IAP in comparison to normal donors. However,
the distributions of antibody values between melanoma
patients and controls were not statistically signiﬁcant
(Wilcoxon rank-sum P = 0.09), nor were there differences
in antibody values for stages I–II melanoma compared with
stages III–IV (Wilcoxon rank-sum P = 0.94).
Overall ML-IAP immunity in melanoma patients
Table 1 summarizes the immune responses to ML-IAP in
stage I–IV melanoma patients and healthy donors (HD). T
cell immunity is reported as responding to one-peptide
pool, two-peptide pools, or three-peptide pools per patient.
Most patients responded to only one-peptide pool, several
responded to two-peptide pools, and only one stage IV
patient responded to three-peptide pools. No individual
responded to more than three-peptide pools. In comparison,
two healthy donors responded to a single peptide pool and
one healthy donor responded to two-peptide pools. The
percentage of patients for each group who had detectable T
cell responses, detectable serologic responses, or either a T
cell or serologic response to ML-IAP are also presented.
For stage I/II patients, 31% had either a cellular or humoral
response, and 5% had both a cellular and humoral response
to ML-IAP, whereas for stage III/IV patients 57 and 14%
were observed, respectively. In comparison, none of the
healthy donors examined had a serologic response to
ML-IAP, and 20% had detectable T cell responses. Taken
together, our data indicate the existence of spontaneous
immune response against ML-IAP in melanoma patients.
Signiﬁcance of immune responses to ML-IAP
in melanoma patients receiving CTLA-4
blockade-based therapy
To further investigate the signiﬁcance of immunity to
ML-IAP, we examined the serologic responses of 10
Fig. 3 T cell responses to ML-IAP HLA-A*0201 epitopes. a Repre-
sentative patient responses. Patient PBMC were pretreated with I280,
JS90, and I237 peptides for 1 week and restimulated with either L11
or the same peptide for ELISPOT analysis. Flu and MART-1 HLA-
A*0201 peptides were utilized for comparison. b Summary of
responses to predicted HLA-A*0201 epitopes from normal donors
and stage I–IV melanoma patients (responders/number tested)
Fig. 4 Generation of CTL to ML-IAP HLA-A*0201 epitopes. PBMC
from HLA-A*0201 donors underwent multiple rounds of stimulation
with CD40L-activated B cells pulsed with IAP237 peptide. CD8
?
cells were further enriched by IFN-c selection and the cells expanded
in the presence of irradiated PBMC, PHA, and IL-2. a ELISPOT
assay for c-IFN production proved speciﬁc IAP237 CD8
? CTL (left
upper panel). Speciﬁcity to HLA-A*0201 activity was further
demonstrated by the ability to block activity with the addition of
the anti-class I antibody W6/32 (left lower panel). Functional
cytotoxicity of manufactured cells was further revealed by CTL
assay utilizing T2 cells in the presence of 10 lg/ml IAP237 peptide
(right panel). The effector to target ratio (E/T) is represented on the
x-axis and percent cytotoxicity is represented on the y-axis. b The
cytolytic activity of IAP237 CTL were further analyzed against HLA-
A2 expressing melanoma cell lines in the absence (left panel)o r
presence of 10 lg/ml IAP237 peptide (right panel). Melanoma cell
line K029 expresses ML-IAP while cell lines K008 and K028 have
very low level of ML-IAP expression. Cell line K008 has lost surface
HLA-A2 expression as determined by ﬂow cytometry
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123patients who received ipilimumab (10 mg/kg) plus bev-
acizumab (15 mg/kg) in a phase I clinical trial. Treatment
dramatically augmented antibody responses against ML-
IAP in two patients as shown by ELISA time course and
immunoblotting (Fig. 5c, d). Moreover, there are no
responses to another IAP family member, survivin (data
not shown). One of these patients had preexisting humoral
immunity to ML-IAP. Both patients experienced signiﬁ-
cant clinical beneﬁt from treatment with stable disease or
partial response for greater than 6 months.
Discussion
ML-IAP is well established as a critical component for
melanoma propagation and survival. The microphthalmia-
associated transcription factor MITF, a known melanoma-
associatedoncogene[29]andcentralregulatorinmelanoma,
has been found to regulate ML-IAP transcription in
melanoma cells [30]. Furthermore, there is an increased
expression of ML-IAP in primary as well as metastatic
melanomas as compared to melanocytic nevi [16]. The
Fig. 5 Humoral immunity of melanoma patients and healthy donors
to recombinant ML-IAP protein. a Puriﬁed recombinant ML-IAP
protein was conﬁrmed by Coomassie blue staining (left panel) and
immunoblotting with ML-IAP-speciﬁc monoclonal antibody [26]
(middle panel). Speciﬁcities of patient humoral responses to ML-IAP
by ELISA were conﬁrmed by immunoblotting using patient sera and
recombinant protein (right panel). b Antibody titers to recombinant
ML-IAP from stage I/II and III/IV melanoma patients and healthy
donor sera as determined by ELISA. Sera from ﬁfteen healthy donors
and sera from ﬁfteen patients representing each stage of disease (60
melanoma patients total) were assayed. Humoral responses of
melanoma patients to recombinant ML-IAP protein after ipilimumab
plus bevacizumab treatment. c Antibody titers to recombinant ML-
IAP from two different patients sera as determined by ELISA.
Pretreatment and treatment time courses are represented. Arrows
represent treatment times. d Speciﬁcities of the patient humoral
responses to ML-IAP by ELISA were conﬁrmed by immunoblotting
using patient sera and ML-IAP recombinant protein
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123signiﬁcance of ML-IAP to tumor cell survival is further
evidenced by the induction of apoptosis through silencing
RNA targeting of ML-IAP [31].
Since most cancers rely on anti-apoptotic mechanisms to
propagate tumor cell growth as well as provide treatment
resistance, the members of the inhibitor of apoptosis family
are highly attractive to fulﬁll this role as functionally sig-
niﬁcant antigens. Spontaneous immune responses to anti-
apoptotic proteins such as Bcl-xL in a variety of cancers
suggest that such immunity may be a generalized event
[32]. The most studied member of the IAP family from an
immune perspective is survivin, found to be the target of
CD4
?, CD8
?, and humoral immune responses in a variety
of cancers [33–40] as well as a tumor rejection antigen in
patients [41]. In comparison, humoral and cellular immune
responses to ML-IAP have sporadically been reported
[27, 40]. Aberrant expression of ML-IAP in lung cancer,
for example, has been associated with the detection of
ML-IAP-speciﬁc CTL in the peripheral blood of patients
[38]. Signiﬁcant antibody titers to ML-IAP have also been
detected in lung cancer, gastrointestinal cancer, and breast
cancer patients [39, 40, 42]. These reports strongly suggest
the broad antigenic potential of ML-IAP in cancer.
The current report reveals spontaneous immune respon-
ses in melanoma patients to an array of ML-IAP epitopes
spanning the protein’s entire sequence. The overlapping
peptide librarywas most sensitive fordetecting CD4
? Tcell
responses. It is possible that CD4
? T cell responses are
present at higher precursor frequency in these patients.
Additionally, MHC class II epitopes have signiﬁcantly
greater promiscuity for binding than class I peptides, likely
contributing to this phenomenon when utilizing 18 mer
peptides in our screening. This approach was nonetheless
able to identify several class I epitopes including the novel
HLA-A*0201 IAP237 peptide. Importantly, the broad cel-
lular immunogenicity of ML-IAP in melanoma patients is
evidenced by the signiﬁcant rate of reactivity revealed in
this screening involving both CD4
? and CD8
? responses.
The importance of ML-IAP to melanoma is highlighted by
the fact that half of all melanoma patients have developed
spontaneous immunity to this antigen. The presence of both
cellular and humoral immune responses in individual
patients suggests potential for coordination of multiple
immune effector mechanisms targeting ML-IAP.
While the frequency of immune responses to ML-IAP
appears higher in melanoma patients, there were detectable
responses in healthy individuals. While not statistically sig-
niﬁcant, there is a trend toward greater frequency of cellular
and humoral immune responses in advanced melanoma
patientsascomparedtoearlierstageorhealthyindividuals.In
addition, spontaneous CTL responses to ML-IAP have been
reported in melanoma patients as well as some healthy indi-
viduals. There may exist a hierarchy of antigens with respect
to their ability to induce spontaneous immune responses in
healthy individuals versus the tumor bearing host.
The ability to generate functional ML-IAP CTL that lyse
targets conﬁrms the signiﬁcance of identiﬁed epitopes and
relevance to the pursuit of targeting ML-IAP for thera-
peutic development. This ability is dependent on the pre-
sentation of naturally processed epitope on the target
surface. Immunodominant HLA-A2 restricted MART-1
epitope has frequently been reported to not be presented on
the surface of melanoma cells [43]. Since immunodomi-
nant epitopes can fail to be presented in some tumors,
dysfunctional regulation of epitope expression in cancer
cells remains a signiﬁcant potential mechanism of tumor
immune evasion. Inadequate epitope presentation on mel-
anoma cell lines utilized in the current study would limit
target killing by CTL, and proliferation of antigen-speciﬁc
CD4
? T cells. Our detection of broad spontaneous immune
responses to ML-IAP via overlapping peptides suggests
that some of these epitopes can naturally be presented. One
limitation in such investigation is the technical difﬁculty to
detect ML-IAP peptides on the surface of melanoma cells.
Development of such methods for peptide detection, for
example mass spectrometry to identify MHC associated
peptides, will likely prove insightful.
The broad immunogenicity of ML-IAP in melanoma
patients further supports its importance as an immune tar-
get for therapeutic development and as a marker of disease.
Three of three patients who had detectable immune
responses to ML-IAP and ﬁve of six who did not have
detectable immune responses exhibited signiﬁcant expres-
sion of ML-IAP in their tumors (1? or greater by
Table 1 Summary of immune responses to ML-IAP in stage I–IV melanoma patients and healthy donors (HD)
Number of
subjects
Number of peptide pool responses T cell
responses (%)
Sera
responses (%)
T cell or Sera
responses (%)
T cell ? Sera
responses (%)
123
Stage I/II 20 5 1 0 24 17 31 5
Stage III/IV 30 7 3 1 37 34 57 14
HD 15 2 1 0 20 0 20 0
Cellular responses for individual patients are reported as responding to one-peptide pool, two-peptide pools, or three-peptide pools. The
percentage of patients for each group who had detectable T cell responses, detectable serologic responses, and either a T cell and/or serologic
response to ML-IAP are presented
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123immunohistochemistry). From available patient tumor
samples, only one lacked expression of ML-IAP in a
patient that did not exhibit detectable cellular or humoral
immune responses. The degree of ML-IAP expression by
immunohistochemistry and development of immune
responses were not able to be directly correlated due to the
small number of pathology samples available in patients
whose PBMC and sera were utilized.
Ipilimumab is a fully human CTLA4 blocking antibody
that is able to augment immune response against melanoma
[44] and has recently been demonstrated to offer a survival
advantage for patients [45]. The improvement in ML-IAP
humoral immunity as a function of treatment not only
validates ML-IAP as an antigen target, but also provides
insight to the mechanism of effective antitumor immunity
of CTLA-4 blockade.
Despite the high incidence of spontaneous immunity
witnessed against ML-IAP in melanoma patients, these
nascent responses were not sufﬁcient to prevent the
development of melanoma or its progression. One possi-
bility for this is the concurrent induction of immune
regulatory pathways that limit the antitumor efﬁcacy of
ML-IAP-speciﬁc immunity. For such cases, intervention
with checkpoint blockade may provide improvement of
ML-IAP effector responses. In addition, there are over-
lapping functions of the anti-apoptotic family members
such that it may be necessary to target other critical pro-
teins, such as survivin, XIAP, and BCL-2.
CTL from the peripheral blood of healthy donors were
manufactured and functional in targeting ML-IAP. This
provides the basis for vaccination and whole cell thera-
peutic approaches. Given its broad expression, its func-
tional importance in tumor propagation, and high incidence
of immune responses in melanoma patients, clinical
investigation targeting ML-IAP is worthy of pursuit.
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